Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis

Overview

Journal Korean Circ J

Date 2023 May 10

PMID 37161680

Authors

Jae Yeong Cho

Dong-Hyuk Cho

Jong-Chan Youn

Darae Kim

Sang Min Park

Mi-Hyang Jung

Junho Hyun

Jimi Choi

Hyun-Jai Cho

Seong-Mi Park

Jin-Oh Choi

Wook-Jin Chung

Byung-Su Yoo

Seok-Min Kang

Affiliations

Soon will be listed here.

Abstract

The Korean Society of Heart Failure guidelines aim to provide physicians with evidence-based recommendations for diagnosing and managing patients with heart failure (HF). In Korea, the prevalence of HF has been rapidly increasing in the last 10 years. HF has recently been classified into HF with reduced ejection fraction (EF), HF with mildly reduced EF, and HF with preserved EF (HFpEF). Moreover, the availability of newer therapeutic agents has led to an increased emphasis on the appropriate diagnosis of HFpEF. Accordingly, this part of the guidelines will mainly cover the definition, epidemiology, and diagnosis of HF.

Citing Articles

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

Huang Y, Chen X, Chen M, Lin Y, Chen B, Gao H Front Pharmacol. 2025; 15:1523136.

PMID: 39881876 PMC: 11775474. DOI: 10.3389/fphar.2024.1523136.

Clinical Implications of a Proteomics-Based Approach for Cardiomyopathy and Heart Failure.

Cho S Korean Circ J. 2024; 54(8):482-484.

PMID: 39109596 PMC: 11306424. DOI: 10.4070/kcj.2024.0194.

Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.

Kim Y, Ahn M, Yoo B, Kim J, Son J, Park Y Int J Heart Fail. 2024; 6(3):119-126.

PMID: 39081646 PMC: 11284333. DOI: 10.36628/ijhf.2023.0052.

Increased risk of cardiovascular disease among kidney cancer survivors: a nationwide population-based cohort study.

Jung M, Choo E, Li S, Deng Z, Li J, Li M Front Oncol. 2024; 14:1420333.

PMID: 39070148 PMC: 11272517. DOI: 10.3389/fonc.2024.1420333.

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years.

Bak M, Youn J, Bae D, Lee J, Lee S, Cho D J Am Heart Assoc. 2024; 13(13):e034055.

PMID: 38904229 PMC: 11255681. DOI: 10.1161/JAHA.123.034055.

References

Maisel A, Mueller C, Adams Jr K, Anker S, Aspromonte N, Cleland J . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9):824-39. DOI: 10.1016/j.ejheart.2008.07.014. View

Solomon S, McMurray J, Anand I, Ge J, Lam C, Maggioni A . Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019; 381(17):1609-1620. DOI: 10.1056/NEJMoa1908655. View

Cho J, Choe W, Cho H, Lee H, Jang J, Lee S . Comparison of Characteristics and 3-Year Outcomes in Patients With Acute Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. Circ J. 2018; 83(2):347-356. DOI: 10.1253/circj.CJ-18-0543. View

Kang S, Park J, Choi D, Yoon C, Oh I, Kang S . Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart. 2015; 101(23):1881-8. DOI: 10.1136/heartjnl-2015-307782. View

Schellenberger U, ORear J, Guzzetta A, Jue R, Protter A, Pollitt N . The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006; 451(2):160-6. DOI: 10.1016/j.abb.2006.03.028. View

Pieske B, Tschope C, de Boer R, Fraser A, Anker S, Donal E . How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020; 22(3):391-412. DOI: 10.1002/ejhf.1741. View

Gao P, Yee R, Gula L, Krahn A, Skanes A, Leong-Sit P . Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging. 2012; 5(4):448-56. DOI: 10.1161/CIRCIMAGING.111.971549. View

Zanotti-Cavazzoni S, Hollenberg S . Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009; 15(5):392-7. DOI: 10.1097/MCC.0b013e3283307a4e. View

Cho D, Son J, Lee C, Choi J, Kim M, Lee J . Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design. Int J Heart Fail. 2022; 4(2):110-116. PMC: 9383348. DOI: 10.36628/ijhf.2022.0005. View

10.

Anand I, Fisher L, Chiang Y, Latini R, Masson S, Maggioni A . Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003; 107(9):1278-83. DOI: 10.1161/01.cir.0000054164.99881.00. View

11.

Shim C . Stress Testing in Heart Failure with Preserved Ejection Fraction. Heart Fail Clin. 2021; 17(3):435-445. DOI: 10.1016/j.hfc.2021.02.007. View

12.

Fonarow G, Peacock W, Horwich T, Phillips C, Givertz M, Lopatin M . Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008; 101(2):231-7. DOI: 10.1016/j.amjcard.2007.07.066. View

13.

Wettersten N . Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment. Int J Heart Fail. 2022; 3(2):81-105. PMC: 9536694. DOI: 10.36628/ijhf.2020.0036. View

14.

Kelder J, Cramer M, Wijngaarden J, van Tooren R, Mosterd A, Moons K . The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011; 124(25):2865-73. DOI: 10.1161/CIRCULATIONAHA.111.019216. View

15.

Gohar A, Rutten F, den Ruijter H, Kelder J, von Haehling S, Anker S . Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail. 2019; 21(10):1219-1227. DOI: 10.1002/ejhf.1495. View

16.

Zairis M, Tsiaousis G, Georgilas A, Makrygiannis S, Adamopoulou E, Handanis S . Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol. 2009; 141(3):284-90. DOI: 10.1016/j.ijcard.2008.12.017. View

17.

Ledwidge M, Gallagher J, Conlon C, Tallon E, OConnell E, Dawkins I . Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013; 310(1):66-74. DOI: 10.1001/jama.2013.7588. View

18.

Myhre P, Vaduganathan M, Claggett B, Packer M, Desai A, Rouleau J . B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019; 73(11):1264-1272. PMC: 7955687. DOI: 10.1016/j.jacc.2019.01.018. View

19.

Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P . Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009; 13(32):1-207, iii. DOI: 10.3310/hta13320. View

20.

Anand I, Kempf T, Rector T, Tapken H, Allhoff T, Jantzen F . Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010; 122(14):1387-95. DOI: 10.1161/CIRCULATIONAHA.109.928846. View